The Latest Breaking News from ChemoCentryx

Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.

 

Here's a roundup of top developments in the biotech space over the last 24 hours:

ChemoCentryx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results.

ChemoCentryx (NASDAQ:CCXI) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ChemoCentryx missed estimated earnings by 83.33%, reporting an EPS of $-0.55 versus an estimate of $-0.3.

ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.30.

ChemoCentryx Inc (NASDAQ:CCXI) announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase 1 study of CCX559 at the American Association for Cancer Research (AACR) Annual Meeting 2022. Preclinical characterization demonstrated that CCX559 is a potent inhibitor of PD-L1 that blocks binding to PD-1 and…

ChemoCentryx (NASDAQ:CCXI) brought in sales totaling $2.31 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 81.68%, resulting in a loss of $40.53 million.